What is Axabin (Rivaroxaban)?
Axabin is an effective, oral anticoagulant developed to prevent and treat dangerous blood clots which has the potential to improve clinical outcomes and quality of life for a wide range of patients with, or at risk of thromboembolism in a broad range of clinical settings.
What is Axabin (Rivaroxaban) approved for?
Axabin is approved for protecting patients across more venous and arterial thromboembolic (VAT) conditions:
Deep vein thrombosis prophylaxis:Postoperative thrombophylaxis of deep vein thrombosis (DVT) which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery.
Deep vein thrombosis treatment: Treatment of DVT.
Pulmonary embolism treatment: Treatment of pulmonary embolism.
Non-valvular atrial fibrillation: Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Reduction in the risk (secondary prevention) of recurrent deep vein thrombosis and/or pulmonary embolism: Reduction in the risk of recurrence of DVT and pulmonary embolism following initial treatment course for DVT and/or pulmonary embolism.
The prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) after an Acute Coronary Syndrome in adult patients with elevated cardiac biomarkers when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine... Read More